Please assess the completion status of the following clinical trial:

Trial Title: Biaxin Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of follicular lymphoma: grades I, II, or IIIA, or non-follicular lymphoma: lymphoplasmacytoid lymphoma, small lymphocytic lymphoma, marginal B-cell lymphoma, or MALT lymphoma (as defined in the WHO classification1) as reviewed by a hematopathologist at Memorial Hospital.~* Staging fulfills criteria for no initial treatment according to GELF criteria for advanced stage disease. None of the following should be present:~  * A nodal or extranodal mass with a diameter of \>7 cm,~ * Involvement of at least three nodal sites \[each with a diameter of \>3 cm\],~ * Systemic symptoms,~ * Symptomatic splenomegaly,~ * Ureteral compression.~ * No prior treatment for lymphoma is permitted.~ * Measurable disease is required.~ * Karnofsky performance status \> 70%~ * The patient may not have a previous history of radiation therapy.~ * Patient or guardian must be able to sign voluntary written consent.~ * Male or female patients 18 years of age or greater.~Exclusion Criteria:~* Allergy to biaxin (clarithromycin), erythromycin, or other macrolide antibiotic. Patients requiring use of ergot derivatives, pimozide, cisapride, or astemizole; combination with ranitidine bismuth citrate should not be used in patients with history of acute porphyria or CrCl \<25 mL/minute.~* Prior treatment with Biaxin (clarithromycin) during the prior 6 months.~* Histologic diagnosis of follicular grade 3B or aggressive non-Hodgkin's lymphoma.~* Histologic evidence of transformation from low grade/indolent NHL to aggressive NHL.~* Prior treatment for non-Hodgkin's lymphoma.~* Regional lymphoma (peripheral stages I and II) eligible for involved field irradiation.~* GELF criteria21 for institution of systemic chemotherapy, which includes:~  * A nodal or extranodal mass with a diameter of \>7 cm,~ * Involvement of at least three nodal sites \[each with a diameter of \>3 cm\],~ * Systemic symptoms,~ * Symptomatic splenomegaly,~ * Ureteral compression.~* Patients with a known history of HIV, Hepatitis B or C seropositivity.~* Patients who require therapy with systemic corticosteroids.~* Prior history of malignancy within the past five years or a concurrent malignancy, with the exceptions of cutaneous basal cell carcinoma or carcinoma in situ of the uterine cervix.~* Pregnant or lactating women, since imaging cannot be done in this setting.18

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): lymphoma follicular
- 2 (Type: None): lymphoma non-follicular

Based on this trial design, predict the completion outcome and termination type (if applicable).